Pacific Biosciences Of California (PACB) Revenue Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn | 7.78% |
| 2 | Stryker | 129.01 Bn | 126.14 Bn | 3.81 Bn | 2.63% |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | 9.86% |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn | 11.58% |
| 5 | Edwards Lifesciences | 48.40 Bn | 44.73 Bn | 1.29 Bn | 16.70% |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | 15.05% |
| 7 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn | 7.41% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.46 Bn | 22.33 Bn | 2.07 Bn | 6.08% |
| 10 | Pacific Biosciences Of California | 414.38 Mn | 138.42 Mn | 12.84 Mn | 0.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.07% |
| Dec 31, 2025 | 13.82% |
| Sep 30, 2025 | -3.82% |
| Jun 30, 2025 | 10.42% |
| Mar 31, 2025 | -4.27% |
| Dec 31, 2024 | -32.79% |
| Sep 30, 2024 | -28.23% |
| Jun 30, 2024 | -24.30% |
| Mar 31, 2024 | -0.23% |
| Dec 31, 2023 | 113.35% |
| Sep 30, 2023 | 72.36% |
| Jun 30, 2023 | 34.13% |
| Mar 31, 2023 | 17.26% |
| Dec 31, 2022 | -24.06% |
| Jun 30, 2022 | 15.87% |
| Mar 31, 2022 | 14.40% |
| Dec 31, 2021 | 32.74% |
| Jun 30, 2021 | 79.25% |
| Mar 31, 2021 | 85.90% |
| Dec 31, 2020 | -2.84% |